MOUD Access in US Jails Lags, Exposing Treatment Gap and Regulatory Risk
Event summary
- A survey of 212 US correctional facilities found only 58% offer medications for opioid use disorder (MOUD).
- Jails are twice as likely to offer MOUD as prisons, with significant regional disparities (West > Midwest > South).
- The South reports the lowest MOUD treatment access, with fewer than 10% of diagnosed individuals receiving treatment.
- The study, funded by Indivior and NCCHC, highlights barriers including stigma, lack of training, and budget constraints.
The big picture
The survey underscores a critical gap in addressing the opioid crisis within the US correctional system, a setting where overdose risk is dramatically elevated. This highlights a misalignment between growing awareness of MOUD's efficacy and its practical implementation, creating both a public health imperative and a potential market opportunity for Indivior. The findings also suggest that regulatory and reimbursement models may need to evolve to incentivize broader adoption of MOUD in correctional facilities.
What we're watching
- Policy Shifts
- Federal attention on addiction treatment could accelerate regulatory pressure on correctional facilities to expand MOUD access, creating both opportunity and compliance risk for Indivior and similar providers.
- Regional Disparities
- The stark regional differences in MOUD availability suggest that state-level policy interventions and funding models will be crucial in driving broader adoption, potentially impacting Indivior's sales strategy.
- Implementation Hurdles
- The persistence of barriers like stigma and provider training indicates that Indivior's success will depend on addressing systemic issues beyond simply providing medication, requiring a broader stakeholder engagement strategy.
Related topics